Dominant mutations in the gene encoding the receptor expression-enhancing protein 1 (*REEP1*) are associated with hereditary spastic paraplegia (HSP), designated SPG31.^[@R1]^ REEP1 is associated with the mitochondria^[@R1]^ and the endoplasmic reticulum (ER) and protects neurons from the accumulation of neurotoxic aggregates.^[@R2]^ *REEP1* mutations account for approximately 3%--10% of autosomal dominant HSPs; *REEP1* is the third most frequent causative gene (following *SPAST* \[spastin\] and *ATL1* \[atlastin 1\]).^[@R3],[@R4]^ More than 40 *REEP1* mutations have been reported to date, comprising mainly small frameshift mutations that are all transmitted in autosomal dominant fashion.^[@R1],[@R3][@R4][@R6]^ Patients with dominant *REEP1* mutations have a slowly progressive "pure" HSP that is only rarely accompanied by peripheral neuropathy.^[@R3][@R4][@R5]^ Only a single family has been described with isolated distal motor neuropathy.^[@R7]^ We report a patient with a recessive *REEP1* mutation with a much more severe phenotype involving severe congenital axonal neuropathy, hyperreflexia, respiratory distress, and distal arthrogryposis, making the clinical phenotype similar to that of patients with spinal muscular atrophy with respiratory distress type 1 (SMARD1).

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

The study was approved by the institutional review board of the Charité (EA1/222/08). Parents provided written informed consent for all aspects of the study according to the Declaration of Helsinki.

Mutation detection. {#s1-2}
-------------------

We performed initial autozygosity mapping followed by whole-exome sequencing (WES) of a consanguineous family with 1 affected patient ([figure 1](#F1){ref-type="fig"}) and 2 healthy siblings. For autozygosity mapping, we investigated the index patient (patient II:03, [figure 2A](#F2){ref-type="fig"}) and 2 healthy siblings (II:01 and II:02) using the Affymetrix 6.0 GeneChip SNP array and performed subsequent analysis using HomozygosityMapper2012 software (<http://www.homozygositymapper.org>) to identify genomic regions that were homozygous solely in the index patient.^[@R8]^ Subsequent WES was performed on the index patient after capture with the SureSelect V4 kit (Agilent Technologies, Santa Clara, CA) and sequencing on a HiSeq 2000 machine (Illumina, San Diego, CA), yielding 82 Mio 2 × 101 bp paired-end reads that were aligned to the human GRCh37.p11 (hg19/Ensembl 72) genomic sequence. The mean coverage was ×112, and 87.9% of the captured sequences were covered more than ×10. After fine adjustment, the raw alignments were called for deviations from the reference in all coding exons ±20 bp flanking regions. Each of these variants was submitted to MutationTaster2 software^[@R9]^ to search for potentially pathogenic variants. These variants were further filtered for a recessive inheritance model (the variant allele occurs in homozygous state in \>20 healthy individuals from the ExAC database release 0.3 \[Exome Aggregation Consortium; Cambridge, MA; [http://exac.broadinstitute.org](http://exac.broadinstitute.org/)\] or \>10 healthy persons in the 1000 Genomes Project) and a dominant inheritance model (the allele was present in \>20 individuals in the 1000 Genomes Project or \>100 individuals from ExAC). Segregation of the mutation with the phenotype in the family was verified by PCR and Sanger sequencing using the BigDye protocol (Life Technologies, Carlsbad, CA) on an ABI 3500 genetic analyzer using following the oligonucleotides: forward: 5′-TCC TTC AAA AGG GCA GTG TT-3′; reverse: 5′-CAC CAC TAT TTC TAA ACA CGT CTC A-3′. Fragment length was analyzed with forward: 5′-TGC TGT CTC CCT ACA CAA AAG-3′ and reverse: FAM-GAA AGA ATG AAA GAC ATG-3′ oligonucleotides.

![Clinical images of the patient\
(A) Talipes equinovarus foot deformity. (B) Arthrogryposis of the hand, with inability to extend the fingers. (C) High-arched palate as a sign of intrauterine muscle weakness. (D) Diaphragmatic palsy with eventration (white arrowheads). (E) Hematoxylin and eosin staining of the quadriceps muscle rules out grouped fiber atrophy. (F) Staining with anti-myosin heavy chain (fast) antibodies reveals fiber type grouping as a sign of denervation/reinnervation. Type II fibers are depicted in brown. (G) Electron microscopy of the neuromuscular endplate reveals condensation of the axoplasm and degeneration of axonal organelles (open arrowhead), including mitochondria and loss of presynaptic neurofilaments, while the subneural clefts appear normal. Five of 5 endplates that could be discovered in the muscle biopsy specimen had identical abnormalities. (H) Normal neuromuscular endplate of the quadriceps muscle of an age-matched control at the same magnification for comparison.](NG2015000778FF1){#F1}

![Molecular genetic findings in the patient\
(A) Pedigree of the consanguineous family. (B) Autozygosity mapping of the family. The red bars depict the candidate regions that comprise 132 protein-coding genes. The genetic coordinates refer to the genome build GRCh37.p11 (hg19/Ensembl 72). (C) GeneScan analysis of the insertion/deletion mutation at the intron 4 splice donor site, with homozygosity for the mutation in the patient and heterozygosity in all other family members. (D) Sequence trace of the mutation on genomic DNA. (E) Investigation of receptor expression-enhancing protein 1 (*REEP1*) on the complementary DNA from cultured fibroblasts verifies skipping of the 121 bp exon 4. No normally spliced transcript was detected in the patient; the mutant bands are faint, possibly because of nonsense-mediated messenger decay. Co = control; mut = mutant band; NTC = nontemplate control; wt = wild-type band.](NG2015000778FF2){#F2}

Reverse transcription PCR on the complementary DNA level. {#s1-3}
---------------------------------------------------------

Index patient and 2 control fibroblast lines were grown to confluency and trypsinized, and total RNA was isolated using the RNeasy Kit (Qiagen, Venlo, the Netherlands) reagent. A further RNA sample was isolated from a muscle biopsy specimen of the patient. Total RNA was reversely transcribed with SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) and random hexamers. Oligonucleotide complementary DNA primers flanking exon 4 (forward: 5′-CCT GCG TAT TAT TCC TAC AAG GC-3′; reverse: 5′-CTT GGA AGC AGC CAT CAC AG-3′) were used for PCR, and the resulting products were separated by agarose electrophoresis and subjected to bidirectional automatic Sanger sequencing.

Histology. {#s1-4}
----------

Processing and staining of muscle cryostat and of transmission electron microscopic samples were performed as described previously.^[@R10],[@R11]^

RESULTS {#s2}
=======

Case report. {#s2-1}
------------

The now 5-year-old boy was born at term after a normal pregnancy to healthy first-cousin parents from Lebanon. Two older brothers are healthy. At birth, the patient presented with an equinovarus foot deformity, contractures of the distal phalanges, and a high-arched palate ([figure 1, A--C](#F1){ref-type="fig"}). Later, progressive distally pronounced weakness and hypotonia, mainly of the lower extremities, became evident. Neurography of the sensory portion of the median nerve revealed axonal neuropathy with reduced amplitudes of 2.9 μV (normal 12.0 ± 5.9 μV) but normal nerve conduction velocity of 43.1 m/s (normal \> 39.7 m/s). We were unable to elicit any measurable motor response or F-waves after stimulation of the median, peroneal, and tibial nerves. EMG could not be performed because of compliance problems. In contrast, muscle tendon reflexes were very brisk with enlarged trigger zones (albeit without upgoing plantar reflexes), indicating upper motor neuron involvement (video 1 at [Neurology.org/ng](10.1212/NXG.0000000000000032)). Mutation analysis of *PMP22, MPZ, GDAP1, EGR2, SH3TC2, IGHMBP2*, and *TRPV4* genes had yielded normal results. Cranial MRI at 6 months was normal. Muscle histology showed fiber type grouping but no relevant atrophy ([figure 1F](#F1){ref-type="fig"}). Electron microscopy of the axons and endplates ([figure 1, G and H](#F1){ref-type="fig"}) demonstrated loss of presynaptic neurofilaments and a condensed axoplasm with degeneration of organelles in the "bouton terminal." Respiratory distress and paradoxical breathing due to diaphragmatic palsy were diagnosed at 11 months ([figure 1D](#F1){ref-type="fig"}, video 2). Following recurrent severe respiratory tract infections with acute respiratory failure, noninvasive nocturnal mask ventilation was initiated at 13 months of age. In recent years, the muscle weakness has not progressed; however, he still cannot sit without support. On the other hand, mental and speech development is apparently normal.

The healthy parents received a thorough clinical neurologic investigation and displayed normal muscle tone, strength, and reflexes as well as normal sensation, fine motor skills, and gait pattern. The only subtle abnormalities were a high palate and a mild increase in the foot arch of the father. Neurography of motor (median, tibial, peroneal) and sensory (median, sural) nerves in both parents showed normal results.

Identification of a *REEP1* mutation. {#s2-2}
-------------------------------------

Autozygosity mapping revealed several regions on chromosomes 1, 2, 10, 11, and 13 (=27.3 Mbp), comprising 132 protein-coding genes. WES revealed 3 homozygous variants within the autozygous regions that were predicted to be potentially disease causing by MutationTaster2 software. Two of them could be excluded (table e-1).

The remaining homozygous splice site mutation in *REEP1* at the donor splice site of exon 4 (c.303+1-7GTAATAT\>AC, p.F62Kfs23\*; NM_022912) was predicted to abrogate the splice site, resulting in a frameshift and premature termination codon after 23 nonoriginal amino acids. This variant was not listed in the ExAC database or the 1,000 Genomes Project as a known polymorphism. Homozygosity of the mutation was confirmed by Sanger sequencing and cosegregated with the phenotype in the family ([figure 2C](#F2){ref-type="fig"}). The splicing defect was verified on the level of the messenger RNA (mRNA) from fibroblasts and muscle ([figure 2E](#F2){ref-type="fig"}). No full-length mRNA transcript was detected in the patient. Repeated Western blots (anti-REEP1, SIGMA SAB2101976, 1:50--1:500) failed to show the presence of the REEP1 protein in extracts from fibroblasts and muscle of the patient and of normal controls, possibly because of low expression levels in these tissues.

Finally, we performed molecular genetic testing of *REEP1* by sequencing all exons in 3 patients from a cohort of patients with a genetically unresolved SMARD1-like phenotype featuring clinical signs of additional involvement of the upper motor neuron. However, we did not detect any further mutation.

DISCUSSION {#s3}
==========

The known heterozygous dominant mutations in *REEP1* are associated with a slowly progressive form of HSP and are only rarely associated with a neuropathy. Only one family with isolated motor axonal neuropathy without any signs of spasticity has been described. Based on functional studies, the authors suspected that heterozygous loss-of-function mutations may result in upper motor neuron pathology, while mutations with a presumed toxic gain of function might cause lower motor neuron disease.^[@R7]^ The \>40 published dominant mutations of *REEP1* are evenly distributed over the entire reading frame, and neither clear genotype--phenotype correlation nor mutational hot spot has been established (figure e-1); recessive mutations have not been reported. Hence the location of the mutation in our family cannot be linked to a special phenotype. Of note, a previously reported mutation (c.303G\>A) of the same exon 4 splice donor was associated with a pure HSP phenotype.^[@R3]^ In a *Reep1*-deficient mouse model, animals developed a severe gait disorder resembling human HSP that was much more pronounced in homozygous animals than in heterozygous animals.^[@R12]^

In our patient, the functional relevance of the splice site mutation could be demonstrated on the mRNA level in fibroblasts and muscle tissue but not on the protein level, presumably because REEP1 expression levels are too low in these tissues to be detectable by Western blot.^[@R1],[@R13]^ It is interesting that the heterozygous parents are healthy despite their obvious haploinsufficiency. These findings may hint at additional factors in the genetic background of the parents with an influence on REEP1-related pathogenicity, although this remains speculative without having investigated further families with a similar phenotype.

A similar constellation was reported for another disease associated with the dominant p.Asn88Ser Berardinelli-Seip congenital lipodystrophy type 2 gene (*BSCL2*) mutation, which had been detected in different unrelated families. This mutation is associated with a broad spectrum of neuromuscular disease phenotypes, ranging from motor neuropathy to complex HSP, but was also seen in asymptomatic heterozygous carriers.^[@R14]^ Of note, homozygous *BSCL2* mutations are known to be associated with an entirely different disorder, congenital generalized lipodystrophy type 2.^[@R15]^

Similar to the BSCL2 protein, REEP1 is localized at the ER and is relevant for ER shaping.^[@R16]^ Recently, it was shown in a *Drosophila* model that overexpression of *reep1* prevents tau-mediated neurodegeneration and promotes neuronal resistance to ER stress.^[@R2]^ Thus, *REEP1*-associated disorders may also be summarized as ER stress diseases, displaying different phenotypes depending on the type of disturbed ER function. However, the precise underlying mechanisms remain to be elucidated.

To date, only a few genes are known to be associated with a SMARD-like phenotype. Both *IGHMBP2* (SMARD1) and *LAS1L* (SMARD2 with X-chromosomal inheritance) play a role in RNA processing, protein translation,^[@R17]^ and ribosomal biogenesis.^[@R18]^ In this respect, a function at the ER might hint at a pathogenetic link between IGHMBP2 and REEP1; however, this requires further experimental evidence. In addition, mutations in the riboflavin transporters *SLC25A2* and *SLC2A3* may also mimic SMARD1, just like mutations in *MEGF10*, a gene involved in the regulation of satellite cells.^[@R19]^ This reflects the clinical and functional heterogeneity of SMARD-like phenotypes.

Our study expands the known phenotypical spectrum of *REEP1*-associated neuromuscular disorders and highlights that recessive *REEP1* mutations should be considered in the genetic workup of patients with a SMARD1-like phenotype, especially if presenting with signs of upper motor neuron involvement.
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